SGO速递丨PARPi耐受性和剂量调整的比较( 二 )
[1]Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416-2428.
[2]Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495-2505.
[3]González-Martín A, Pothuri B, Vergote I, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2391-2402.
[4]William Bradley, Kathleen Moore, Nicoletta Colombo, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1. SGO 2021.
[5]Melissa M. Hardesty, Thomas Krivak, Gail S. Wright, et al. Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Frontline Platinum-Based Chemotherapy with Bevacizumab. SGO 2021, Poster #22.
[6]Rebecca Arend, David M O'Malley, Susana Banerjee, et al. Comparative tolerability and dose modifications of poly(ADP-ribose) polymerase inhibitors in ovarian cancer: a retrospective cohort study of US healthcare claims data. SGO 2021, Poster 10487.
推荐阅读
- ASCO2021丨在可切除的非小细胞肺癌中,新辅助免疫联合化疗优于单独化疗
- EHA中国之声丨张磊教授:我国儿童ET的现状及特点,一项真实世界研究
- 罕见血型|较真丨江苏南京出现“万能血”,能救所有人,别人却救不了自己?
- 神谷旅游扶贫超市丨足不出户,尽享便利
- 好物分享丨减肥还管不住嘴?减脂零食快看一看,嘴馋星人必备
- ASCO热评丨朱耀教授:一项最大规模前列腺癌基因组研究和一项基因组分类风险评估研究的启示
- 新闻多一度丨端午将至,你选甜粽还是咸粽?
- 人间有爱丨尿酸的那些事儿
- 漳州正兴急诊科丨5分钟院内生命急救系统“时刻准备着”
- NSCLC丨FDA批准首个针对KRAS G12C突变靶向药物,G360 CDx等成伴随诊断!
